Accessibility Menu
Diagnos Stock Quote

Diagnos (OTC: DGNOF)

$0.21
(4.2%)
+0.01
Price as of February 6, 2026, 12:12 p.m. ET

KEY DATA POINTS

Current Price
$0.21
Daily Change
(4.2%) +$0.01
Day's Range
$0.21 - $0.21
Previous Close
$0.21
Open
$0.21
Beta
0.22
Volume
1,000
Average Volume
124,982
Market Cap
$26M
Market Cap / Employee
$0.21M
52wk Range
$0.13 - $0.29
Revenue
N/A
Gross Margin
-16.46%
Dividend Yield
N/A
EPS
-$0.03
CAPs Rating
N/A
Industry
Health Care Technology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Diagnos Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
DGNOF-10.31%-50.51%-13.1%-83%
S&P+13.95%+78.35%+12.25%+400%

Diagnos Company Info

Diagnos, Inc. engages in the provision of healthcare technical services through the use of artificial intelligence (AI). The company offers algorithm development, data analysis, and image processing services. It focuses on the development of its AI tool, Computer Assisted Retina Analysis, which is a tele-ophthalmology platform that integrates with existing equipment and processes at the point of care. The company was founded by Djamel Abdelkader Zighed in 1998 and is headquartered in Brossard, Canada.

News & Analysis

No results found

No news articles found for Diagnos.

Financial Health

General

Q3 2025YOY Change
Revenue$11.01K-33.8%
Gross Profit-$261.68K-23.3%
Gross Margin-2377.60%-1100.6%
Market Cap$22.12M-12.1%
Net Income-$796.00K-6.5%
EBITDA-$709.45K-14.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q3 2025YOY Change
Net Cash$352.59K-3.1%
Accounts Receivable$12.47K-8.6%
Inventory00.0%

Liabilities

Q3 2025YOY Change
Long Term Debt$241.08K-75.7%
Short Term Debt$1.47M4.3%

Ratios

Q3 2025YOY Change
Return On Assets-230.59%-55.3%
Return On Invested Capital-679.01%-131.8%

Cash Flow

Q3 2025YOY Change
Free Cash Flow-$658.05K-43.9%
Operating Free Cash Flow-$655.30K-44.9%

Valuation

MetricQ4 2024Q1 2025Q2 2025Q3 2025YoY Change
Price to Book-25.90-58.1784.09-37.64194.15%
Price to Sales199.28283.56228.47364.4379.91%
Price to Tangible Book Value-25.90-58.2184.09-37.65194.31%
Enterprise Value to EBITDA-25.47-24.13-20.43-30.68-18.73%
Total Debt$2.28M$2.13M$1.83M$1.72M-28.72%

No results found

No podcast episodes available.

No results found

No transcripts available.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.